NIMble innovation—a networked model for public antibiotic trials
Summary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | The Lancet Microbe |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666524721001828 |
| _version_ | 1819010246154125312 |
|---|---|
| author | Rebecca E Glover, PhD Andrew C Singer, PhD Adam P Roberts, PhD Claas Kirchhelle, PhD |
| author_facet | Rebecca E Glover, PhD Andrew C Singer, PhD Adam P Roberts, PhD Claas Kirchhelle, PhD |
| author_sort | Rebecca E Glover, PhD |
| collection | DOAJ |
| description | Summary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline. |
| first_indexed | 2024-12-21T01:09:13Z |
| format | Article |
| id | doaj.art-aacf5652e8a54576992a5c2ec4b50189 |
| institution | Directory Open Access Journal |
| issn | 2666-5247 |
| language | English |
| last_indexed | 2024-12-21T01:09:13Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | The Lancet Microbe |
| spelling | doaj.art-aacf5652e8a54576992a5c2ec4b501892022-12-21T19:20:58ZengElsevierThe Lancet Microbe2666-52472021-11-01211e637e644NIMble innovation—a networked model for public antibiotic trialsRebecca E Glover, PhD0Andrew C Singer, PhD1Adam P Roberts, PhD2Claas Kirchhelle, PhD3Department of Health Services Research and Policy, Faculty of Public Health Policy, London School of Hygiene & Tropical Medicine, London, UKUK Centre for Ecology & Hydrology, Wallingford, UKDepartment of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, UKSchool of History, University College Dublin, Dublin, Ireland; Correspondence to: Dr Claas Kirchhelle, School of History, University College Dublin, Dublin 4, IrelandSummary: Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline.http://www.sciencedirect.com/science/article/pii/S2666524721001828 |
| spellingShingle | Rebecca E Glover, PhD Andrew C Singer, PhD Adam P Roberts, PhD Claas Kirchhelle, PhD NIMble innovation—a networked model for public antibiotic trials The Lancet Microbe |
| title | NIMble innovation—a networked model for public antibiotic trials |
| title_full | NIMble innovation—a networked model for public antibiotic trials |
| title_fullStr | NIMble innovation—a networked model for public antibiotic trials |
| title_full_unstemmed | NIMble innovation—a networked model for public antibiotic trials |
| title_short | NIMble innovation—a networked model for public antibiotic trials |
| title_sort | nimble innovation a networked model for public antibiotic trials |
| url | http://www.sciencedirect.com/science/article/pii/S2666524721001828 |
| work_keys_str_mv | AT rebeccaegloverphd nimbleinnovationanetworkedmodelforpublicantibiotictrials AT andrewcsingerphd nimbleinnovationanetworkedmodelforpublicantibiotictrials AT adamprobertsphd nimbleinnovationanetworkedmodelforpublicantibiotictrials AT claaskirchhellephd nimbleinnovationanetworkedmodelforpublicantibiotictrials |